ALTERNATING USE OF DIFFERENT JAK1/JAK2 INHIBITORS, A POSSIBLE THERAPEUTIC STRATEGY USEFUL IN PRIMARY MYELOFIBROSIS: A CASE REPORT

被引：0
|
作者：
Gutierrez, Lopez de Ocariz X. [1 ]
Vera, Guerrero E. [1 ]
Carreno, Gomez-Tarragona G. [1 ]
Buendia, Urena B. [1 ]
De Nicolas, Sol R. [1 ]
Hidalgo, Soto M. [1 ]
Lopez, Munoz N. [1 ]
Zamanillo, Herreros, I [1 ]
Iniguez, Garcia R. [1 ]
Poza, Santaella M. [1 ]
Ayala, Diaz R. [1 ]
Martinez, Lopez J. [1 ]
机构：
[1] Hosp Univ 12 Octubre, Madrid, Spain
来源：
HAEMATOLOGICA | 2020年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB-059
引用
收藏
页码：395 / 395
页数：1
相关论文
共 50 条
  • [31] Presence of triple positive driver mutations in JAK2, CALR and MPL in primary myelofibrosis: a case report and literature review
    Zhao, Long
    Zhang, Hao
    Chen, Juan
    Ma, Haizhen
    Liu, Bei
    HEMATOLOGY, 2024, 29 (01)
  • [32] Identification of C-2 Hydroxyethyl Imidazopyrrolopyridines as Potent JAK1 Inhibitors with Favorable Physicochemical Properties and High Selectivity over JAK2
    Zak, Mark
    Hurley, Christopher A.
    Ward, Stuart I.
    Bergeron, Philippe
    Barrett, Kathy
    Balazs, Mercedesz
    Blair, Wade S.
    Bull, Richard
    Chakravarty, Paroma
    Chang, Christine
    Crackett, Peter
    Deshmukh, Gauri
    DeVoss, Jason
    Dragovich, Peter S.
    Eigenbrot, Charles
    Ellwood, Charles
    Gaines, Simon
    Ghilardi, Nico
    Gibbons, Paul
    Gradl, Stefan
    Gribling, Peter
    Hamman, Chris
    Harstad, Eric
    Hewitt, Peter
    Johnson, Adam
    Johnson, Tony
    Kenny, Jane R.
    Koehler, Michael F. T.
    Kohli, Pawan Bir
    Labadie, Sharada
    Lee, Wyne P.
    Liao, Jiangpeng
    Liimatta, Marya
    Mendonca, Rohan
    Narukulla, Raman
    Pulk, Rebecca
    Reeve, Austin
    Savage, Scott
    Shia, Steven
    Steffek, Micah
    Ubhayakar, Savita
    van Abbema, Anne
    Aliagas, Ignacio
    Avitabile-Woo, Barbara
    Xiao, Yisong
    Yang, Jing
    Kulagowski, Janusz J.
    JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (11) : 4764 - 4785
  • [33] Allogeneic Stem Cell Transplantation in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms Pretreated with JAK1/JAK2 Inhibitors
    Barabanshikova, Maria
    Morozova, Elena
    Moiseev, Ivan
    Vlasova, Julia
    Baykov, Vadim
    Ushal, Inna
    Rodionov, Gennadij
    Moiseev, Sergey
    Barkhatov, Ildar
    Afanasyeva, Ksenija
    Bondarenko, Sergey
    Afanasyev, Boris
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 402 - 403
  • [34] Different CALR mutation subtypes in essential thrombocythemia and primary myelofibrosis patients without JAK2 mutation
    Layla M. Saleh
    Reem Algamal
    Hanaa Abd Elmasseh
    Emily Barber
    Hasan Abdel-ghaffar
    memo - Magazine of European Medical Oncology, 2020, 13 : 235 - 243
  • [35] Different CALR mutation subtypes in essential thrombocythemia and primary myelofibrosis patients without JAK2 mutation
    Saleh, Layla M.
    Algamal, Reem
    Abd Elmasseh, Hanaa
    Barber, Emily
    Abdel-ghaffar, Hasan
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2020, 13 (02) : 235 - 243
  • [36] Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls
    Verstovsek, Srdan
    Kantarjian, Hagop M.
    Estrov, Zeev
    Cortes, Jorge E.
    Thomas, Deborah A.
    Kadia, Tapan
    Pierce, Sherry
    Jabbour, Elias
    Borthakur, Gautham
    Rumi, Elisa
    Pungolino, Ester
    Morra, Enrica
    Caramazza, Domenica
    Cazzola, Mario
    Passamonti, Francesco
    BLOOD, 2012, 120 (06) : 1202 - 1209
  • [37] Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2
    Labadie, Sharada S.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 246
  • [38] Ruxolitinib, a JAK1/2 Inhibitor as Treatment for Paraneoplastic Pemphigus: A Case Report
    Fan, Birao
    Wang, Mingyue
    ACTA DERMATO-VENEREOLOGICA, 2022, 102
  • [39] Remission of necrobiosis lipoidica diabeticorum with a JAK1/2 inhibitor: A case report
    Barbet-Massin, M. -A.
    Rigalleau, V.
    Blanco, P.
    Mohammedi, K.
    Poupon, P.
    Belin, E.
    Poursac, N.
    Cadart, O.
    Blanco, L.
    DIABETES & METABOLISM, 2021, 47 (04)
  • [40] Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2
    Labadie, Sharada
    Dragovich, Peter S.
    Barrett, Kathy
    Blair, Wade S.
    Bergeron, Philippe
    Chang, Christine
    Deshmukh, Gauri
    Eigenbrot, Charles
    Ghilardi, Nico
    Gibbons, Paul
    Hurley, Christopher A.
    Johnson, Adam
    Kenny, Jane R.
    Kohli, Pawan Bir
    Kulagowski, Janusz J.
    Liimatta, Marya
    Lupardus, Patrick J.
    Mendonca, Rohan
    Murray, Jeremy M.
    Pulk, Rebecca
    Shia, Steven
    Steffek, Micah
    Ubhayakar, Savita
    Ultsch, Mark
    van Abbema, Anne
    Ward, Stuart
    Zak, Mark
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (24) : 7627 - 7633
12345